throMboembolic Risk Associated To High atrIal Fibrillation riSk

Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Study ID
NCT07441759
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Artificial Intelligence (AI)
  • Atrial Fibrillation (AF)
  • Cardio Vascular Disease
  • Cardio-cerebrovascular Disease
  • Cost-effectiveness Analysis
  • Electronic Health Records
  • MACE
  • Quality-adjusted Life-years
  • Thromboembolic Risk

Eligibility Criteria

Sex
ALL
Age
65 Years - 95 Years
Healthy Volunteers
Accepted

Interventions

  • AI_MATHIAS — PROCEDURE
    MATHIAS-guided strategy (intervention): This approach was applied to the high-risk cohort (Q4) \[10,24\] to estimate individual thromboembolic risk. The process included a subsequent clinical evaluation and device-based photoplethysmography screening \[5,11\], followed by AI-driven thromboembolic risk stratification using the MATHIAS AI prototype \[35,36\] with initiation of oral anticoagulation according to the predicted risk profile, regardless of whether atrial fibrillation was confirmed or not.

Study Details

Cardiovascular diseases are the leading cause of mortality from treatable conditions in the European Union and the second from preventable causes, with a standardized mortality rate of 257.8 deaths per 100,000 inhabitants. In 2022, more than 1.11 million deaths in individuals under 75 years could have been avoided. Atrial fibrillation (AF) and major adverse cardiovascular events (MACE) are highly prevalent in the elderly and generate substantial healthcare costs. AF significantly increases the risk of MACE and is projected to rise markedly in the coming decades. In Europe, AF prevalence is expected to increase 2.5-fold over the next 50 years, with a lifetime risk of 1 in 3-5 individuals after age 55. AF-related strokes are projected to increase by 34%, and ischemic strokes in individuals over 80 are expected to triple between 2016 and 2060. Additionally, a 27% increase is anticipated among stroke survivors who subsequently develop AF or related conditions. AF substantially impacts morbidity, mortality, and disease progression, and early detection and treatment are crucial to prevent severe outcomes. European action plans (2018-2030) and the 2024 ESC/ESO guidelines emphasize early detection and management of AF in primary care. Although several AF prediction models exist, their integration into clinical practice remains challenging. AF represents a clinical continuum, with thrombotic risk present even before arrhythmia onset. High-risk patients for AF also show a high incidence of MACE, defined as a composite of myocardial infarction, stroke, systemic embolic events, and cardiovascular death. The proposed strategy involves developing and clinically validating an Artificial Intelligence (AI) model to improve early thrombotic risk prediction in patients at high risk of AF, using MACE as the primary outcome. This model aims to outperform the traditional CHA₂DS₂-VASc score by incorporating both classical and emerging clinical factors. The estimated timeline from clinical validation to commercialization is approximately 48 months. AI-based prediction is expected to enable personalized treatment, reduce the incidence of MACE, hospitalizations, and disability, and improve cost-effectiveness, ultimately decreasing the social and economic burden of AF and stroke in Europe.

Key Dates

First listed
Mar 2, 2026
Start date
Jul 6, 2026
Status verified
Feb 2026
Primary completion
Oct 29, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
1,000 participants (estimated)

Arms

  • Arm: control
    Usual care (comparator): Opportunistic AF detection during routine clinical encounters and anticoagulation guided by the CHA₂DS₂VA score in patients with documented AF, without any AI-based pre-AF risk assessment. This approach reflects current guideline-concordant practice in many European primary care settings, where AF digital screening has not yet been implemented.

Primary Outcome Measure

Primary Outcome Measures 1. Incidence of First-Ever and Recurrent Stroke [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts

Related Studies